Sage Therapeutics, Inc.
SAGE evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Lead Asset:
- ZULRESSO (Approved)
What it means
What to watch
Prepared research question
What matters most for SAGE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 2 pipeline candidates · 5 clinical trials · 1 FDA decision for Sage Therapeutics, Inc..
Similar companies
Run Sage Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Sage Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is Sage Therapeutics, Inc.'s lead drug candidate?
Sage Therapeutics, Inc.'s most advanced tracked candidate is ZULRESSO (Approved) for Postpartum depression (PPD) in individuals 15 years old and older.
Who is the CEO of Sage Therapeutics, Inc.?
Business Conduct is the chief executive officer of Sage Therapeutics, Inc. (SAGE).
What therapeutic areas does Sage Therapeutics, Inc. focus on?
Sage Therapeutics, Inc. develops therapies across Rare Disease, Neurology, Immunology, Pain, Dermatology, Musculoskeletal, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.